Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 1999

View Archived Issues

SuperGen to acquire Sparta stock and development portfolio

ZymeTx reports progress in development programs

Nippon Kayaku: Annual Report 1998

55 new chemical entities in the combined AstraZeneca pipeline

Phase II trial of G-3139 in NHL patients to commence at Royal Marsden Hospital

Monsanto: Q4 and year-end 1998 highlights

Searle's celecoxib: the first COX-2 inhibitor reaches the market

Pfizer's new macrolide antibiotics presented in patent literature

Beyond Viagra: FDA reviews new product approvals in 1998

Potent heterocyclic antithrombotic agents discovered by Lilly

Neurotransmitter reuptake-inhibitory piperidines designed at NeuroSearch

British Biotech continues search for MMP inhibitors

Preparation and use of neuronal NOS inhibitors disclosed by Astra

New 5-HT4 receptor ligands from Synthelabo, their synthesis and use

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Therapeutic advantages of paricalcitol further defined

Alpha-Beta Technology discontinues phase III trial of Betafectin

Oral L-arginine compared to placebo for efficacy in interstitial cystitis

Glaxo Wellcome and PowderJect expand DNA vaccine collaboration

Searle drops development of gpIIb/IIIa receptor antagonists

New insulin sensitizer is a coligand for PPARalpha and PPARgamma receptors

L-754030 will enter phase III testing for emesis

Another significant market introduction for basiliximab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...